Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
CP Wu, SH Hsiao, YS Wu - Drug Resistance Updates, 2023 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …
Recent advances in boosting EGFR tyrosine kinase inhibitors-based cancer therapy
Q Pan, Y Lu, L Xie, D Wu, R Liu, W Gao… - Molecular …, 2023 - ACS Publications
Epidermal growth factor receptor (EGFR) plays a key role in signal transduction pathways
associated with cell proliferation, growth, and survival. Its overexpression and aberrant …
associated with cell proliferation, growth, and survival. Its overexpression and aberrant …
The ABCG2/BCRP transporter and its variants–from structure to pathology
The ABCG2 protein has a key role in the transport of a wide range of structurally dissimilar
endo‐and xenobiotics in the human body, especially in the tissue barriers and the …
endo‐and xenobiotics in the human body, especially in the tissue barriers and the …
Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance
Tyrosine kinases (TKs) play an important role in pathways that regulate cancer cell
proliferation, apoptosis, angiogenesis and metastasis. Aberrant activity of TKs has been …
proliferation, apoptosis, angiogenesis and metastasis. Aberrant activity of TKs has been …
Reversing chemotherapy resistance by a synergy between lysosomal pH-activated mitochondrial drug delivery and erlotinib-mediated drug efflux inhibition
F Cheng, Q Pan, W Gao, Y Pu, K Luo… - ACS Applied Materials & …, 2021 - ACS Publications
Mitochondrial drug delivery has attracted increasing attention in various mitochondrial
dysfunction-associated disorders such as cancer owing to the important role of energy …
dysfunction-associated disorders such as cancer owing to the important role of energy …
[HTML][HTML] Carbonic anhydrase XII is a new therapeutic target to overcome chemoresistance in cancer cells
J Kopecka, I Campia, A Jacobs, AP Frei, D Ghigo… - Oncotarget, 2015 - ncbi.nlm.nih.gov
Multidrug resistance (MDR) in cancer cells is a challenging phenomenon often associated
with P-glycoprotein (Pgp) surface expression. Finding new ways to bypass Pgp-mediated …
with P-glycoprotein (Pgp) surface expression. Finding new ways to bypass Pgp-mediated …
Avapritinib: a selective inhibitor of KIT and PDGFRα that reverses ABCB1 and ABCG2-mediated multidrug resistance in cancer cell lines
CP Wu, S Lusvarghi, JC Wang, SH Hsiao… - Molecular …, 2019 - ACS Publications
The frequent occurrence of multidrug resistance (MDR) conferred by the overexpression of
ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 in cancer cells remains a …
ATP-binding cassette (ABC) transporters ABCB1 and ABCG2 in cancer cells remains a …
Advances in emerging drugs for osteosarcoma
CM Hattinger, M Fanelli, E Tavanti, S Vella… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Osteosarcoma (OS), the most common primary malignant bone tumor, is
currently treated with pre-and postoperative chemotherapy in association with the surgical …
currently treated with pre-and postoperative chemotherapy in association with the surgical …
Folate-targeted liposomal nitrooxy-doxorubicin: An effective tool against P-glycoprotein-positive and folate receptor-positive tumors
E Gazzano, B Rolando, K Chegaev… - Journal of controlled …, 2018 - Elsevier
Drug efflux transporters, in particular P-glycoprotein (Pgp), limit the success of
chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide …
chemotherapy. We previously found that synthetic doxorubicin conjugated with nitric oxide …
Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase
FJ Giles, HM Kantarjian, PD Le Coutre, M Baccarani… - Leukemia, 2012 - nature.com
Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and
imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML) in chronic …
imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML) in chronic …